RC is a 58-year-old female presenting with early-onset Alzheimer’s disease. Her labs reveal a vitamin D deficiency (22 ng/mL), but otherwise stable thyroid, B12, hemoglobin, and glucose parameters
SCENARIO 3
RC is a 58-year-old female that presents to the clinic today with early-onset Alzheimer’s Disease. What would you prescribe? Consider her labs and provide a drug therapy plan. Include complete medication orders. How would you monitor therapy? Labs: TSH 3.4 mU/L, vitamin D 22 ng/mL, B12 501 pg/mL, Hgb 12.8 g/dL, BG 96 mg/dL, A1C 5.9%, BP 115/72, HR 76. Medications include: Tresiba 15 units SC once daily QHS, Novolog 5 units SC before each meal TID (adjusting based on carbohydrate intake and glucose monitoring), and lisinopril 10 mg po daily
RC is a 58-year-old female presenting with early-onset Alzheimer’s disease. Her labs reveal a vitamin D deficiency (22 ng/mL), but otherwise stable thyroid, B12, hemoglobin, and glucose parameters
Scenario 3: RC – Early-Onset Alzheimer’s Disease
RC is a 58-year-old female presenting with early-onset Alzheimer’s disease. Her labs reveal a vitamin D deficiency (22 ng/mL), but otherwise stable thyroid, B12, hemoglobin, and glucose parameters. She is already on insulin therapy for diabetes and lisinopril for blood pressure. Management should focus on initiating therapy to slow cognitive decline while correcting nutritional deficiency.
Drug Therapy Plan
Donepezil 5 mg po once daily at bedtime, #30 tablets, 2 refills
Class
: Acetylcholinesterase inhibitor.
MOA
: Inhibits acetylcholinesterase in the CNS, increasing acetylcholine levels and enhancing cholinergic neurotransmission to slow cognitive decline (Kumar et al., 2023).
Cholecalciferol (Vitamin D3) 2000 IU po once daily, #30 capsules, 2 refills
Class
: Vitamin D supplement.
MOA
: Enhances calcium absorption and bone mineralization; correcting deficiency also supports cognitive and overall health (Al-Hashimi & Abraham, 2024).
GET A HUMAN-WRITTEN PAPER NOW
Monitoring
Cognitive function using standardized tools (MMSE or MoCA) every 6–12 months (Wang et al., 2022).
Monitor for donepezil adverse effects (nausea, diarrhea, insomnia, bradycardia) (Kumar et al., 2023).
Recheck serum vitamin D in 3 months.
Continue monitoring BP, A1C, and renal function due to comorbid conditions.
Patient Education
Donepezil is not curative, but it may slow symptom progression.
Take at bedtime to minimize GI upset.
Encourage physical activity, cognitive stimulation, and good sleep hygiene.
Stress adherence to vitamin D supplementation.
RC is a 58-year-old female presenting with early-onset Alzheimer’s disease. Her labs reveal a vitamin D deficiency (22 ng/mL), but otherwise stable thyroid, B12, hemoglobin, and glucose parameters
Leave a Reply